Amneal Pharmaceuticals Inc

Latest Results (05.01.2025):

Net Revenue Growth

Amneal Pharmaceuticals Inc. reported net revenue of $702 million for the third quarter of 2024, marking a 13% increase from the $620 million recorded in the same quarter of 2023. This growth was driven by strong performances in both the Generics and Specialty segments, with notable contributions from new product launches and biosimilars.

Net Loss and Earnings

For the third quarter of 2024, Amneal Pharmaceuticals Inc. reported a GAAP net loss of $0.2 million, compared to a net income of $10 million in the third quarter of 2023. The diluted loss per share was $0.00, primarily due to higher interest expenses impacting net income.

Adjusted EBITDA and EPS

Amneal Pharmaceuticals Inc. achieved an adjusted EBITDA of $158 million in the third quarter of 2024, reflecting a 2% increase from the previous year. The adjusted diluted earnings per share stood at $0.16, slightly down from $0.19 in the third quarter of 2023, influenced by a $20 million R&D milestone payment.

Segment Performance

The Generics segment of Amneal Pharmaceuticals Inc. saw a 9% increase in net revenue, while the Specialty segment experienced a 19% rise, driven by promoted products in neurology and endocrinology. Additionally, the AvKARE segment reported a 21% increase in net revenue, supported by growth in distribution and government label sales channels.

2024 Full Year Guidance

Amneal Pharmaceuticals Inc. reaffirmed its full-year 2024 guidance, projecting net revenue between $2.70 billion and $2.80 billion. The company anticipates adjusted EBITDA to range from $610 million to $630 million, with adjusted diluted EPS expected to be between $0.57 and $0.63, alongside operating cash flow estimates of $280 million to $320 million.